Is This The Smartest Stock to Buy?
Smartsheet isn’t a company on the tip of most retail traders tongues but it might be soon. What started out as a spreadsheet with collaborative project management features has grown into a work management software worth $5.7 billion.
Better yet, it’s growing at a rapid rate and is sitting squarely in the middle of a market that is forecast to grow at 13.4% annually through 2026. » Read more about: Is This The Smartest Stock to Buy? »
Read More
1 Warren Buffett Stock to Buy Hand Over Fist
Legendary investor Warren Buffett and his company, Berkshire Hathaway, are known for savvy stock picking. Certainly, he’s had his fair share of duds – look no further than IBM – but he’s also made enormously successful bets ($100+ billion gain on Apple alone is a classic recent example). Another successful addition has been Visa.
Although Berkshire Hathaway sold roughly 4% of its stake in Visa in Q3,
» Read more about: 1 Warren Buffett Stock to Buy Hand Over Fist »
Read More
How A US Champion Trader Generated 941.1%
A trader named Oliver Kell is creating a buzz in the investing world after winning the 2020 U.S. Investment Championship with an annual 941 percent return – a return almost twice that of his closest competitor. That eye-popping number has earned Kell many interviews and a lot of coverage in digital and print media.
So how did Kell develop this strategy that enabled him to make such big gains?
» Read more about: How A US Champion Trader Generated 941.1% »
Read More
Is Planet.com A Hidden Gem?
» Read more about: Is Planet.com A Hidden Gem? »
Read More
Priceless Advice From Legendary Investor
If you’ve been around the investing block a few times you know the old jokes about stocks falling the second you buy them. Peter Lynch, the legendary investor who averaged a 29.2% return from 1977 to 1990 doesn’t shy from plunging stocks like most others, though. Instead he embraces it and calls corrections for what they truly are.
» Read more about: Priceless Advice From Legendary Investor »
Read MoreThe Burst
Market Commentary: The Meteoric Rise of Eli Lilly
Did you know that Eli Lilly and other pharmaceutical companies have sold approximately 10.6 million shots of obesity drug doses in the U.S. in a single month? The rise of these injectable weight loss medications is so powerful that it’s causing investors to question the future of even staple food and beverage stocks.
While this aspect alone could secure Eli Lilly as the pharmaceutical golden goose you’ve been looking for there is much more than meets the eye.
» Read more about: Market Commentary: The Meteoric Rise of Eli Lilly »
Read MoreThe Spotlight
The Daily
Federal Reserve’s fiscal management shamed over ballooning $2.5 billion office renovation
The ballooning price tag for the $2.5 billion renovation of the Federal Reserve’s Washington, D.C. headquarters has become the pressure point for efforts by President Trump and his administration to force the central bank’s chairman, Jerome Powell, to either lower interest rates or step aside.
Since the beginning of his second term,